EMR Versus ESD for Barrett's Neoplasia

Rationale: The optimal technique for removal of visible dysplastic lesions in Barrett's esophagus remains controversial. Endoscopic mucosal resection (EMR) is safe, effective, easy to apply, and has been the most widely used technique since 2008. Endoscopic submucosal dissection (ESD) is a more controlled dissection method with potential improved efficacy, but at the cost of higher technical complexity. Objective: The investigators aim to compare EMR and ESD for removal of visible lesions in Barrett's esophagus. Study design: Randomized clinical trial Study population: Patients with Barrett's esophagus and a visible lesion with dysplasia and/or early cancer. Suspicion for submucosal invasion is an exclusion criterion. Intervention: Patients are randomized to receive either EMR or ESD, with follow-up and no ablation during 12 months after the resection. Main study endpoint: Primary endpoint is the proportion of patients with no evidence of residual or local recurrent neoplasia during 12 months follow-up after baseline.

NCT Number	NCT05276791
Lead Sponsor	St. Antonius Hospital Collaborators: University Medical Center Groningen, Erasmus Medical Center, UMC Utrecht, Amsterdam University Medical Center, Catharina Ziekenhuis Eindhoven
Conditions	Barretts Esophagus With Dysplasia, Barrett Adenocarcinoma, Esophageal Cancer
Enrollment	331 participants
Start Date	2023-01-17
Primary Completion	2027-12-01 (estimated)
Study Completion	2028-12-01 (estimated)
Updated on ClinicalTrials.gov	2026-06-29